Lilly Blocked From Selling Boehringer's Tradjenta Until At Least May 31
This article was originally published in The Pink Sheet Daily
Executive Summary
Judge says Lilly would be sharing confidential Amylin data by having its Byetta sales reps promote Tradjenta; Lilly plans to increase its diabetes sales force from 774 to 1,144.
You may also be interested in...
Lilly Sales Reps Resume Launch Of BI's Tradjenta; Judge Says FDA Regs Protect Byetta
FDA advertising regs protect Amylin's Byetta from being maligned, judge says in lifting temporary restraining order against Lilly.
Lilly Sales Reps Resume Launch Of BI's Tradjenta; Judge Says FDA Regs Protect Byetta
FDA advertising regs protect Amylin's Byetta from being maligned, judge says in lifting temporary restraining order against Lilly.
Caught Between Two Partners: Amylin Seeks To Block Lilly's Byetta Sales Force From Marketing Tradjenta
Amylin claims Lilly has breached its agreement to commercialize exenatide as the Big Pharma gears up to launch the Boehringer-developed diabetes drug Tradjenta.